Earlier this month, industry watchers questioned who could swallow the reportedly on-the-block Tesaro and its $7.5 billion-plus market cap. Now, though, it seems a pair of M&A-starved drugmakers may be interested in trying.
Sanofi, Gilead said to be eyeing potential $10B deal for prime cancer target Tesaro
Leave a Comment